HK1202433A1 - Methods and uses of anp (atrial natriuretic peptide , bnp (brain natriuretic peptide and cnp (c-type natriuretic peptide -related peptides and derivatives thereof for treatment of retinal disorders and diseases anp( bnp( cnp(c - Google Patents

Methods and uses of anp (atrial natriuretic peptide , bnp (brain natriuretic peptide and cnp (c-type natriuretic peptide -related peptides and derivatives thereof for treatment of retinal disorders and diseases anp( bnp( cnp(c

Info

Publication number
HK1202433A1
HK1202433A1 HK15103021.0A HK15103021A HK1202433A1 HK 1202433 A1 HK1202433 A1 HK 1202433A1 HK 15103021 A HK15103021 A HK 15103021A HK 1202433 A1 HK1202433 A1 HK 1202433A1
Authority
HK
Hong Kong
Prior art keywords
natriuretic peptide
cnp
anp
bnp
diseases
Prior art date
Application number
HK15103021.0A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Kozlowski
Original Assignee
Kalos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalos Therapeutics Inc filed Critical Kalos Therapeutics Inc
Publication of HK1202433A1 publication Critical patent/HK1202433A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103021.0A 2011-12-16 2015-03-25 Methods and uses of anp (atrial natriuretic peptide , bnp (brain natriuretic peptide and cnp (c-type natriuretic peptide -related peptides and derivatives thereof for treatment of retinal disorders and diseases anp( bnp( cnp(c HK1202433A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576720P 2011-12-16 2011-12-16
PCT/US2012/070190 WO2013090931A2 (en) 2011-12-16 2012-12-17 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases

Publications (1)

Publication Number Publication Date
HK1202433A1 true HK1202433A1 (en) 2015-10-02

Family

ID=48613379

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103021.0A HK1202433A1 (en) 2011-12-16 2015-03-25 Methods and uses of anp (atrial natriuretic peptide , bnp (brain natriuretic peptide and cnp (c-type natriuretic peptide -related peptides and derivatives thereof for treatment of retinal disorders and diseases anp( bnp( cnp(c

Country Status (7)

Country Link
US (1) US20150045301A1 (ja)
EP (1) EP2790714A4 (ja)
JP (2) JP2015502368A (ja)
CN (2) CN108653715A (ja)
CA (1) CA2853204A1 (ja)
HK (1) HK1202433A1 (ja)
WO (1) WO2013090931A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CA2559853A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US20070049251A1 (en) 2005-08-31 2007-03-01 Mock Von A Method and system for wireless communication in emergency situations
JP2010539010A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデスロレリンおよびマストパランの使用
WO2009033762A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of endothelin-3 as a therapeutic agent
KR20100057641A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
JP2010538994A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 例えば肺炎連鎖球菌感染症を治療するためのｂｆｇｆ１−２４および任意での（ａｒｇ８）バソプレシンの使用
JP2011509248A (ja) * 2007-12-28 2011-03-24 カルロス・セラピューティクス、インク 抗細胞増殖化合物およびその使用方法
WO2011038066A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
JP5893561B2 (ja) * 2009-09-25 2016-03-23 シャイア・オーファン・セラピーズ・ゲーエムベーハーＳｈｉｒｅ Ｏｒｐｈａｎ Ｔｈｅｒａｐｉｅｓ ＧｍｂＨ 新規ｎｐｒ−ｂアゴニスト
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders

Also Published As

Publication number Publication date
CA2853204A1 (en) 2013-06-20
JP2018024674A (ja) 2018-02-15
EP2790714A4 (en) 2015-08-05
EP2790714A2 (en) 2014-10-22
CN104039341A (zh) 2014-09-10
WO2013090931A2 (en) 2013-06-20
US20150045301A1 (en) 2015-02-12
WO2013090931A3 (en) 2013-10-31
CN108653715A (zh) 2018-10-16
JP2015502368A (ja) 2015-01-22

Similar Documents

Publication Publication Date Title
IL281376A (en) Medicinal peptides of neuregulin for the treatment or prevention of heart failure
HK1215283A1 (zh) 用於調節膽汁酸體內穩態以及治療膽汁酸紊亂和疾病的方法
IL256004A (en) History of chloropyrazine carboxamide used in the treatment of diseases preferentially in insufficient hydration of the mucosa
IL229185B (en) A system and method for correcting heart rhythm irregularities using a designed amputation
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
HK1210211A1 (en) Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf (bdnf) bdnf
HK1202064A1 (en) Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions c15
HK1198333A1 (zh) 抗纖維化肽及其在用於治療以纖維化為特徵的疾病和病症的方法中的用途
ZA201309557B (en) Methods of treatment for retinal diseases
PH12015501271A1 (en) Stabilized insulin-like growth factor polypeptides
ZA201400167B (en) Treatment of respiratory disorders using trpa1 antagonists
HK1202433A1 (en) Methods and uses of anp (atrial natriuretic peptide , bnp (brain natriuretic peptide and cnp (c-type natriuretic peptide -related peptides and derivatives thereof for treatment of retinal disorders and diseases anp( bnp( cnp(c
EP2925363A4 (en) METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
EP3077412A4 (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
EP2773365A4 (en) PEPTIDE ANALOGS FOR THE TREATMENT OF ILLNESSES AND SUFFERING
EP2722389A4 (en) METHOD FOR INCREASING PRODUCTION YIELD OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS